ロード中...
Rosiglitazone and Gemcitabine in combination reduces immune suppression and modulates T cell populations in pancreatic cancer
Pancreatic ductal adenocarcinoma is a leading cause of cancer mortality with a dismal 2–5 % 5-year survival rate. Monotherapy with Gemcitabine has limited success, highlighting the need for additional therapies that enhance the efficacy of current treatments. We evaluated the combination of Gemcitab...
保存先:
| 主要な著者: | , , , , |
|---|---|
| フォーマット: | Artigo |
| 言語: | Inglês |
| 出版事項: |
Springer-Verlag
2012
|
| 主題: | |
| オンライン･アクセス: | https://ncbi.nlm.nih.gov/pmc/articles/PMC3873637/ https://ncbi.nlm.nih.gov/pubmed/22864396 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1007/s00262-012-1324-3 |
| タグ: |
タグ追加
タグなし, このレコードへの初めてのタグを付けませんか!
|